MétaCan
Menu
Back to cohort
Record W2894922801 · doi:10.1186/s13063-018-2900-4

Outcome measures in clinical trials of treatments for acute severe haemorrhage

2018· letter· en· W2894922801 on OpenAlexaff
Amy Brenner, Mònica Arribas, Jack Cuzick, Vipul Jairath, Simon Stanworth, Katharine Ker, Haleema Shakur‐Still, Ian Roberts

Bibliographic record

VenueTrials · 2018
Typeletter
Languageen
FieldMedicine
TopicTrauma, Hemostasis, Coagulopathy, Resuscitation
Canadian institutionsWestern University
FundersHealth Technology Assessment ProgrammeMedical Research CouncilBupa FoundationNational Institutes of HealthCancer Research UKWellcome TrustBill and Melinda Gates FoundationPfizerNational Institute for Health and Care Research
KeywordsMedicineCause of deathClinical trialBleedIntensive care medicinePsychological interventionRandomized controlled trialEmergency medicineSurgeryDiseaseInternal medicine

Abstract

fetched live from OpenAlex

BACKGROUND: Acute severe haemorrhage is a common complication of injury, childbirth, surgery, gastrointestinal pathologies and other medical conditions. Bleeding is a major cause of death, but patients also die from non-bleeding causes, the frequency of which varies by the site of haemorrhage and between populations. Because patients can bleed to death within hours, established interventions inevitably take priority over randomisation into a trial. These circumstances raise challenges in selecting appropriate outcome measures for clinical trials of haemostatic interventions. MAIN BODY: We use data from three large randomised controlled trials in acute severe haemorrhage (CRASH-2, WOMAN and HALT-IT) to explore the strengths and limitations of outcome measures commonly used in trials of haemostatic treatments, including all-cause and cause-specific mortality, blood transfusion and surgical interventions. Many deaths following acute severe haemorrhage are due to patient comorbidities or complications rather than bleeding. If non-bleeding deaths are unaffected by a haemostatic intervention, even large trials will have low power to detect an effect on all-cause mortality. Due to the dilution from deaths unaffected or reduced by the trial treatment, all-cause mortality can also obscure important harmful effects. Additionally, because the relative contributions of different causes of death vary within and between patient populations, all-cause mortality is not generalisable. Different causes of death occur at different time intervals from bleeding onset, with bleeding deaths generally occurring early. Time-specific mortality can therefore be used as a proxy for cause in un-blinded trials where bias is a concern or in situations where cause of death cannot be assessed. Urgent treatment is critical, and so post-randomisation blood transfusion and surgery are often planned before or at the time of randomisation and therefore cannot be influenced by the trial treatment. CONCLUSIONS: All-cause mortality has low power, lacks generalisability and can obscure harmful effects. Cause-specific mortality, such as death due to bleeding or thrombosis, avoids these drawbacks. In certain scenarios, time-specific mortality can be used as a proxy for cause-specific mortality. Blood transfusion and surgical procedures have limited utility as outcome measures in trials of haemostatic treatments.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.374
metaresearch head score (Gemma)0.560
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: Methods
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.626
Threshold uncertainty score0.772

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.3740.560
Meta-epidemiology (narrow)0.0040.001
Meta-epidemiology (broad)0.0130.014
Bibliometrics0.0050.007
Science and technology studies0.0020.006
Scholarly communication0.0070.007
Open science0.0030.005
Research integrity0.0090.009
Insufficient payload (model declined to judge)0.0160.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.553
GPT teacher head0.560
Teacher spread0.006 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designNot applicable
DomainMethods
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations41
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueTrialsSame topicTrauma, Hemostasis, Coagulopathy, ResuscitationFrench-language works237,207